SCI makes their human embryonic germ cell platform commercially available in Europe

Chicago, 12 April 2006, At Bio2006 Stem Cell Innovations, Inc. (SCLL.OB) announced today that the Company will commercialize their proprietary platform of human pluripotent stem cells in Europe through their newly established European R & D facility in Leiden, the Netherlands.

CEO Dr. James Kelly recently disclosed that SCI has produced multiple lines of human pluripotent stem cells. These cell lines are able to maintain their undifferentiated state and normal chromosome complement. The cells are produced without feeder layers (xenofree). The company is able to efficiently develop multiple lines, the first step in creating banks of cells that can be matched to patients in cell therapies.

To be able to serve the European market and to make the cells available to both scientists in Academia and the European Pharma and Biotech industry, SCI will produce stem cell lines in Leiden as well as in Houston, Texas.

● About Stem Cell Innovations, Inc.
Stem Cell Innovations, through its wholly owned subsidiary, Amphioxus Cell Technologies, which is based in Houston, Texas, is a cell biology company. It utilizes its proprietary C3A human liver cell line in the field of drug discovery and toxicology testing and is also engaged in the development and production of its proprietary PC™ pluripotent stem cells. These human cell-based disease models create a platform for the discovery, testing and development of all therapeutic modalities including small molecules, cell-based therapeutics, small interfering RNAs and antibodies.

Contact Information

James H. Kelly

Chief Executive Officer

Stem Cell Innovations, Inc.

Contact via E-mail